Indian company chooses Aagami for Out-Licensing to the US market, an innovatively developed on the market anti-infective asset

Published : 07 Jan 2014


 Aagami has been chosen by an Indian company, a first win. It has been appointed by an Indian company for Out Licensing their innovatively developed anti-infective asset for the US market. Aagami looks forward to supporting its first ever Indian client to find an appropriate product company in the US market. The company has launched this asset successfully in India in Jan 2013 and partnered it for Latin America and South Africa. The asset is also about to receive market authorisation in Europe.

Aagami CEO stated "We are very proud that now we have companies from India trusting us for their out licensing and partnering needs for the US market. This proves our track record of supporting global companies around the world. We are looking forward to bring to the US companies this innovation from India."

About the client:
The company specialises in the high-growth injectable segments like anti-infective, oncology, cardiovascular and neurology. It is among the world's 10 leading fixed dosage injectable manufacturers and has presence in 60 countries, covering more than 75 products. Their R&D division has more than 55 scientists and has been working on many innovative programs in different stages. Their pipeline is strong and the top management is quite keen to play with top innovators of the world.


×
Twitter